August 2012
-
HDT Bio announced that it has received a grant of ~$1.8 million from the US Army Medical Research Acquisition Activity for development of the company’s HDT-201 RNA-based nasal spray for the prevention and treatment of… Read more . . .
-
Canadian biotech Ceapro announced the expansion of an existing collaboration with McMaster University for development of inhaled yeast beta glucans for the prevention and treatment of lung fibrosis caused by COVID-19. According to Ceapro, the… Read more . . .
-
Harm Reduction Therapeutics announced that it has signed a commercial supply agreement for its RiVive (HRT001) intranasal naloxone after the FDA granted Fast Track designation to the nasal spray, which is in development as a… Read more . . .
-
Aridis Pharmaceuticals said that its AR-701 inhaled monoclonal antibody cocktail effectively reduced viral load in rhesus macaques infected with SARS-CoV-2 and protected against lung disease in those animals over a 5-day period. The company received… Read more . . .
-
Opiant Pharmaceuticals said that it has received an additional $2.1 million from the US Biomedical Advanced Research and Development Authority (BARDA) to support regulatory activities related to its OPNT003 intranasal nalmefene for the treatment of opioid overdose. BARDA had… Read more . . .
-
Verona Pharma said that the Phase 3 ENHANCE-2 trial of nebulized ensifentrine for treatment of COPD met its primary endpoint, with an average change from baseline in FEV1 AUC, 0-12 hours post dose, of 94… Read more . . .
-
The University of Glasgow announced that Innovate UK has awarded a university spinout, Acu-Flow, £1 million for development of the company’s Nebu-Flow surface acoustic wave nebulizer technology. The University said that its researchers will work… Read more . . .
-
Aptar Pharma announced that it has acquired worldwide rights to Pharmaxis’ high payload Orbital dry powder inhaler. In August 2021, the company said that it had acquired an option to purchase the rights to the Orbital… Read more . . .
-
According to Inhalation Sciences (ISAB), the FDA will provide up to $500,000 over two years to fund a study intended to validate ISAB’s DissolvIt in vitro lung simulation model for dissolution testing of inhaled drugs.… Read more . . .
-
Just over a week after receiving 510(k) clearance for a Hailie inhaler sensor for use with Ellipta DPIs, Adherium said that it filed a 510(k) submission to the FDA for a new Hailie sensor to… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.